AstraZeneca's Wainua Stumbles: The Clinic Pushed Back on Pharma's Deal Boom

GSK is taking a decade-old cancer drug into one of the rarest, highest-stakes settings in oncology — and it's filing with the FDA on the strength of a single Phase 2 win.

Meanwhile Q32 Bio grew hair on heads that JAK inhibitors couldn't touch, the FDA finalized its psychedelics playbook, LEQEMBI just went at-home, and tau data is landing all week at AAIC. Loaded Monday. Let's get into it.

Welcome to The Pharma Closeout for Monday, July 13th. I'm Alex Mercer.

And I'm Maya Patel.

GSK said this morning it plans to file Jemperli with the FDA in a small but high-profile cancer use, after a Phase 2 win. The reporting points to rectal cancer. And the word "small" is doing a lot of misleading work here — because this is the setting where dostarlimab first became famous.

Locally advanced mismatch-repair-deficient rectal cancer. And the goal there isn't shrinking a tumor. It's organ preservation — avoiding surgery, avoiding radiation, avoiding permanent, life-altering consequences. This is curative intent in a population that's been defined by how brutal the treatment is.

So walk the franchise with me. Jemperli's already approved with chemo in frontline endometrial cancer — started in the dMMR subset, then expanded to all adults, including the mismatch-repair-proficient group that's seventy to seventy-five percent of patients. This rectal filing takes the same PD-1 antibody into an entirely different tumor. On Phase 2 data.

OK, but here's my issue with calling this a franchise-expansion win. A Phase 2 filing in a rare dMMR slice of rectal cancer is a tiny commercial number. Small pool. If you're building this into a revenue model, you're going to be disappointed.

That's fair on the dollars. But the value isn't the rectal revenue — it's the label story and the halo around it. A curative-intent, organ-preservation approval changes how oncologists and payers think about the entire mechanism in mismatch-repair-deficient disease.

Then the sharper read is this: rectal is a flag, not a market. It tells you GSK is building dostarlimab into the dMMR drug — one biomarker, multiple tumors — and the payoff shows up in the endometrial franchise's positioning and durability, not in rectal scripts.

And that lands directly on Merck. Keytruda owns the tumor-agnostic mismatch-repair story. The competitive read: if you're running oncology strategy and you've treated dMMR as Merck's turf, GSK just planted a flag in the one setting — curative-intent rectal — where the data narrative is hardest to argue with.

The open question is the label. Phase 2 gets you a filing; it doesn't get you a broad indication. Watch whether the FDA takes this as a defined dMMR rectal population or asks for confirmatory work — because that one decision is what separates a symbolic approval from the anchor of a real franchise.

Now, the readout that moved a stock today — Q32 Bio. Bempikibart hit the primary goal of a Phase 2a alopecia areata study, shares spiked. Maya, this is the comeback story.

It is — Q32 had a prior setback, so "bounces back" is earned. The 36-week data from Part B: roughly two-fifths of the 33 patients grew enough hair to cover 80% of the scalp. No Grade 3 or higher adverse events, no new safety signals. And the trial included patients already treated with JAK inhibitors. That last piece is the tell.

Unpack that for me — why does the JAK detail carry the story?

Because the market's already anchored by the JAKs, Litfulo and Olumiant. A new mechanism doesn't win by matching them. It wins by working in the patients they failed, or with a safety story that sidesteps the class warnings. Thirty-three patients is small, Phase 2a is early — but activity in a post-JAK population is what makes this a program worth watching, not a me-too.

Staying on the pipeline, two more moves worth flagging. Agenus scrapped a Phase 3 colorectal study just three months in — narrowing its focus to an MSS colon cancer trial after its earlier combo missed on response rate. And GSK's got a second bit of good news: its Hansoh-partnered ADC extended survival in a lung cancer study.

The Agenus pivot is the discipline story, not the failure story. Killing a Phase 3 at three months to concentrate on the population where the biology actually reads — that's a company managing cash and probability instead of chasing a headline. Given where the funding environment is, that's the right instinct.

Which is the backdrop I wanted to hit. No fresh mega-deal today, but it's been an extraordinary year going into earnings — Vertex's $10 billion Crinetics buy the most recent marker we flagged a week back. And the weekend reset the mood: Friday's selloff took Moderna down 11%, ImmunityBio and Sarepta both off 8%, the XBI down 4%. Pure profit-taking after a parabolic run. No company-specific catalyst. Monday's tape only made it worse — SK Hynix's record drop, Strait of Hormuz risk-off, everything red.

And the financing signal underneath is the real story. BioPharma Dive has the highest first-half VC total since early 2022 — but a widening gap. The capital is concentrating in companies already in human testing. Early-stage startups are getting left behind.

You see it in the IPO window too. Generate Biomedicines is targeting a $2.17 billion valuation, raising $425 million, and Apnimed just filed as the FDA reviews its sleep apnea drug. Meanwhile health tech pulled in $7.4 billion in the first half. The through-line: capital's paying up for de-risked, in-human assets and punishing speculation — which is exactly when the disciplined buyers go shopping.

On the regulatory front, the FDA finalized its psychedelics guidance this morning and scheduled a broader Part 15 hearing for September. This is the scaffolding a first psychedelic approval would stand on — and Compass Pathways' COMP360 is the program most directly in frame, with a potential approval by year-end.

And Compass has been laying the durability groundwork — they've said the depression benefit is long-lasting.

Which is the exact pressure point. The challenge with psychedelics was never whether patients respond. It's functional unblinding and durability. Guidance that actually engages with those design problems is worth more to the field than any single readout — because it tells every sponsor what a registrational trial has to look like before they spend a dollar building one.

Also worth noting on the regulatory side — a fresh approval landed today. Eisai and Biogen's LEQEMBI cleared a subcutaneous, once-weekly initiation dose. At-home autoinjector, launching late August.

That's the meaningful shift for the anti-amyloid class — initiation moves out of the infusion chair. Efficacy doesn't change. Access and the cost of delivering the therapy do — and that rewrites the reimbursement math far more than the headline suggests.

The rejection-letter pause is also over — the FDA just posted 14 new ones. Hengrui and Elevar's PD-1 liver cancer combo got turned down a third time. There's also a CRL for Tris Pharma's narcolepsy drug. And the agency proposed streamlining registration for hub-and-spoke manufacturing and foreign API producers — right in step with the onshoring push.

A third strike on the same combo isn't noise, it's a message. For anyone holding a partnered China-origin PD-1 asset, the bar for combinations in crowded indications is not bending your way. And read those 14 letters closely — most of what the FDA flagged is quality and facilities, not efficacy. That's the agency telling you where its attention actually sits.

Looking ahead, tau owns the week at AAIC. Biogen presents Phase 2 CELIA data on diranersen, its tau-targeting antisense drug. Voyager's got early tau data on VY1706.

And here's the Biogen line I'd watch. The May topline was framed as the first study to show both reduced tau pathology and cognitive benefit — but the reporting around whether it actually hit its primary endpoint has been mixed. AAIC is where the full dataset either backs that framing or undercuts it. Don't take the press-release adjective as the result.

Sharp. Also on the calendar: the FDA's call on rivoceranib plus camrelizumab in frontline liver cancer is due July 23rd, and the earnings cycle opens — where every big pharma gets asked the same question about M&A appetite in this tape.

So the week tests two things at once. Whether tau lives up to the amyloid-era hype. And whether a jittery market rewards clean data or just keeps rotating out. We'll know a lot more in five days.

And that is your Pharma Closeout for Monday, July 13th — GSK pushing Jemperli into curative-intent rectal cancer, Q32 Bio's comeback hair data, a finalized psychedelics framework, and LEQEMBI moving to the autoinjector. This industry does not slow down, and honestly, we love it. If you're not already subscribed, this is the week to fix that — we'll be back tomorrow with the first read on the AAIC tau data.

And that's the one I can't wait to dig into. Go make your Monday count. See you tomorrow!